𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium

✍ Scribed by Yves Berthezëne; Andreas Mühler; Philipp Lang; David M. Shames; Olivier Clëment; Werner Rosenau; Ryohei Kuwatsuru; Robert C. Brasch

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
645 KB
Volume
3
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This study evaluated the pharmacokinetics and potential toxicity of inhaled aerosolized gadopen‐tetate dimeglumine. The pharmacokinetics were evaluated with in vitro relaxometry of the lungs, blood, urine, and liver before and for up to 36 hours after a 5‐minute inhalation of aerosolized gadopen‐tetate dimeglumine (0.25 mol/L). For assessment of potential toxicity, hemodynamic variables were monitored during and for 10 minutes after inhalation. Extravascular lung water was measured before and after exposure. Finally, the potential for tissue damage was evaluated histologically. Pulmonary clearance of aerosolized gadopentetate dimeglumine was monoexponential with a half‐time of 2.16 hours. Aerosolized gadopentetate dimeglumine was excreted through the kidneys, as shown by the decrease in urinary T1. Renal elimination was completed by 30 hours. No acute hemodynamic effect, histologic change, or induction of edema was demonstrated. This study shows that inhalation of aerosolized gadopentetate dimeglumine is well tolerated in rats and favors the further evaluation of this administration route, including clinical trials.

📜 SIMILAR VOLUMES

Inhaled corticosteroids: Clinical releva
Inhaled corticosteroids: Clinical relevance of safety measures
✍ John F. Price 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB

There seem to be individual, end organ, and tissue variations in responsiveness to glucocorticoids. In some children, 400-800 µg/day of inhaled steroid reduces cortisol excretion and short-term growth of the lower leg. These effects only become clinically relevant if the capacity of the adrenal glan

Tolerability and safety aspects of mirta
Tolerability and safety aspects of mirtazapine
✍ David J. Nutt 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

The tolerability and safety profile of the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine reflects its unique pharmacological profile. The 5-HT(2) blocking effect contributes towards its anxiolytic effects and benefits on sleep, as well as preventing the sexual dysfunctio

Safety of gadolinium-DTPA: Extended clin
Safety of gadolinium-DTPA: Extended clinical experience
✍ H. P. Niendorf; J. Haustein; I. Cornelius; A. Alhassan; W. Clauß 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB

## Abstract This review reports data on the general and renal tolerance of the paramagnetic contrast agent Gd‐DTPA after intravenous administration. Gd‐DTPA was administered usually at a dose level of 0.1‐0.2 mmol/kg body wt (range: 0.005‐0.25 mmol/kg body wt) in cranial, spinal and body MR indicat

Ethical aspects of technical safety
Ethical aspects of technical safety
✍ Carl Friedrich Gethmann 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

## Abstract Uncertainty and inequality are the most important phenomena that lead to the situation in which the modern technical age, in contrast to the premodern technical phase, gives rise to specifically moral problems which in the premodern era played only a marginal role or no role at all. So

Pharmacokinetics and safety of single or
Pharmacokinetics and safety of single oral doses of lomefloxacin
✍ Dr. Irwin S. Morse 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

The pharmacokinetics of 100 mg, 200 mg, 400 mg, 600 mg, and 800 mg of lomefloxacin, a quinolone antimicrobial, were examined in a single sequential rising dose, placebocontrolled, crossover study. Each of 30 healthy male subjects (6 per group) received placebo and one dose of lomefloxacin, separated